%0 Journal Article
%A Genescà, Eulàlia
%A Morgades, Mireia
%A González-Gil, Celia
%A Fuster-Tormo, Francisco
%A Haferlach, Claudia
%A Meggendorfer, Manja
%A Montesinos, Pau
%A Barba, Pere
%A Gil, Cristina
%A Coll, Rosa
%A Moreno, María-José
%A Martínez-Carballeira, Daniel
%A García-Cadenas, Irene
%A Vives, Susana
%A Ribera, Jordi
%A González-Campos, José
%A Díaz-Beya, Marina
%A Mercadal, Santiago
%A Artola, María-Teresa
%A Cladera, Antonia
%A Tormo, Mar
%A Bermúdez, Arancha
%A Vall-Llovera, Ferran
%A Martínez-Sánchez, Pilar
%A Amigo, María-Luz
%A Monsalvo, Silvia
%A Novo, Andrés
%A Cervera, Marta
%A García-Guiñon, Antonio
%A Ciudad, Juana
%A Cervera, José
%A Hernández-Rivas, Jesús-María
%A Granada, Isabel
%A Haferlach, Torsten
%A Orfao, Alberto
%A Solé, Francesc
%A Ribera, Josep-Maria
%T Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
%D 2021
%U http://hdl.handle.net/10668/18008
%X The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
%K Adult T-ALL
%K Cytogenetics
%K NGS
%K Prognosis
%K Therapy
%~